Private EquityScreenerRefer

MARKET INSIGHTS

  • EventsNEWPrivate market milestones
  • NewsPrecize daily pulse
  • BlogsIn-depth articles and opinions

GUIDES

Explore Now
  • Unlisted SharesStep-by-step · KYC
  • BuyingStep-by-step · KYC
  • SellingExit in 24 - 48 hours
  • Pre-IPOReturns · risks · case studies
  • Tax GuideBudget 2026 changes
  1. Home
  2. Shares
  3. Veeda Clinical Research

Veeda Clinical Research Unlisted Share Price Today

ISIN INE01HQ01026.

About Company Veeda Clinical Research is an India-based clinical research organization (CRO), providing integrated services across the drug development lifecycle to global pharmaceutical and biotechnology companies. The company primarily focuses on early-phase clinical research, including Phase I studies, bioequivalence and bioavailability studies, food-effect studies, and experimental medicine trials.  Veeda operates through a science-led, asset-intensive model supported by in-house cli…

Veeda Clinical Research

Login for availability
Veeda Clinical Research

Veeda Clinical Research Unlisted Share Price Today

Current Price
Login for availability
Loading chart data...
SectorHealthcare & Pharmaceuticals
ISININE01HQ01026
Depository
Market Cap₹2,992.88 Cr
P/E Ratio-43.05
ROE (%)-6.93
Revenue₹609.73 Cr
Book ValueN/A
Debt to EquityN/A
Face Value2
52W High₹464
52W Low₹442
Market Cap₹2,992.88 Cr
P/E Ratio-43.05
ROE (%)-6.93
Revenue₹609.73 Cr
Book ValueN/A
Debt to EquityN/A
52W High/Low₹464 / ₹442
Face Value2
As of FY25

About the company & Industry

About Company

Veeda Clinical Research is an India-based clinical research organization (CRO), providing integrated services across the drug development lifecycle to global pharmaceutical and biotechnology companies. The company primarily focuses on early-phase clinical research, including Phase I studies, bioequivalence and bioavailability studies, food-effect studies, and experimental medicine trials. 

Veeda operates through a science-led, asset-intensive model supported by in-house clinical, bioanalytical, and regulatory capabilities, enabling it to serve complex and regulated clinical programs. Its long-term client engagements and repeat business underpin a scalable operating model with scope for operating leverage as capacity utilisation improves.

About Company

Veeda Clinical Research is an India-based clinical research organization (CRO), providing integrated services across the drug development lifecycle to global pharmaceutical and biotechnology companies. The company primarily focuses on early-phase clinical research, including Phase I studies, bioequivalence and bioavailability studies, food-effect studies, and experimental medicine trials. 

Veeda operates through a science-led, asset-intensive model supported by in-house clinical, bioanalytical, and regulatory capabilities, enabling it to serve complex and regulated clinical programs. Its long-term client engagements and repeat business underpin a scalable operating model with scope for operating leverage as capacity utilisation improves.

Financials

Income Statement

Revenue(Figures in Cr.)

Income Statement

Revenue(Figures in Cr.)

Competitive Position

Market Share

P/E Ratio

Financial Ratio Comparison (FY25)

Particulars
Veeda Clinical Research
Syngene
Sai Life Sciences
Revenue (₹ Cr)609.733642.401694.57
Revenue Growth (%)56.834.4115.66
EBITDA Margin (%)22.3731.4526.11
Net Profit Margin (%)-10.9613.6210.04
ROE (%)-6.9311.0510.96
Debt to Equity1.160.030.06
ROCE (%)-0.79--
Working Capital Intensity (%)4.6924.4645.56
Asset Turnover (x)0.310.560.62
ROA (%)-3.42--
Capex Intensity (%)24.0420.0531.00

Market Share

P/E Ratio

Financial Ratio Comparison (FY25)

Particulars
Veeda Clinical Research
Syngene
Sai Life Sciences
Revenue (₹ Cr)609.733642.401694.57
Revenue Growth (%)56.834.4115.66
EBITDA Margin (%)22.3731.4526.11
Net Profit Margin (%)-10.9613.6210.04
ROE (%)-6.9311.0510.96
Debt to Equity1.160.030.06
ROCE (%)-0.79--
Working Capital Intensity (%)4.6924.4645.56
Asset Turnover (x)0.310.560.62
ROA (%)-3.42--
Capex Intensity (%)24.0420.0531.00

Management

Shareholding PatternAs of FY26
Basil Private Limited
35.83%
Bondway Investment Inc
19.20%
Other Investors
44.97%

Key Managerial Personnel

As of FY26
NameDesignation and Experience
Dr. Mahesh Kantilal Bhalgat
Chairman & Managing Director
Mr. Nirmal Bhatia
Chief Financial Officer

Shareholding PatternAs of FY26
Basil Private Limited
35.83%
Bondway Investment Inc
19.20%
Other Investors
44.97%

Key Managerial Personnel

As of FY26
NameDesignation and Experience
Dr. Mahesh Kantilal Bhalgat
Chairman & Managing Director
Mr. Nirmal Bhatia
Chief Financial Officer
Coming Soon

Register to view prices and access exclusive investments.

Minimum ticket ₹10,000 - Start small. No large capital lock-in.
Reserve Access
or
Continue with Google
Reserve Access

FAQs on Veeda Clinical Research Unlisted Shares

What is the unlisted share price today?

unlisted share price is updated regularly on Precize. Visit Precize to check price movements and market trends.

How do I buy unlisted shares?

Register on Precize.in, complete KYC, select , enter quantity, and pay via UPI or NEFT. Shares are transferred within 24 hours.

What is 's revenue and profitability?

Please read these important legal notices and disclosures

None of the information displayed on or downloadable from https://www.precize.in represents an offer to buy or sell or a solicitation of an offer to buy or sell any security, nor does it constitute an offer to provide investment advice or service. Registered representatives of precize do not (1) Advise any member on the merits or advisability of a particular investment or transaction, or (2) Assist in the determination of fair value of any security or investment, or (3) Provide legal, tax, or transactional advisory services.

Read more

© 2026 Precize All Rights Reserved.

DECLARATION OF RISKTERMS OF USEPRIVACY POLICY
reported revenue of ₹609.73 Cr in FYFY25. PAT was ₹N/A Cr. See full financials on this page.

What is the minimum investment for unlisted shares?

Minimum investment for unlisted shares starts from ₹10000. Please log in to view the latest pricing and availability